PATRYS Ltd (PAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PATRYS Ltd (PAB) has a cash flow conversion efficiency ratio of -2.365x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.73 Million ≈ $-1.23 Million USD) by net assets (AU$732.87K ≈ $518.56K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PATRYS Ltd balance sheet independence to measure how much of total assets are equity-financed.
PATRYS Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how PATRYS Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PAB operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
PATRYS Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PATRYS Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PYRAMID AG NA KONV.
XETRA:M3B0
|
0.092x |
|
Hunting PLC
LSE:HTG
|
0.046x |
|
Irisity AB
ST:IRIS
|
-0.017x |
|
Mason Graphite Inc.
V:LLG
|
-0.007x |
|
Watta Holding Bhd
KLSE:7226
|
-0.009x |
|
Touchwood Entertainment Limited
NSE:TOUCHWOOD
|
-0.092x |
|
Robogroup
TA:ROBO
|
-0.260x |
|
Kentima Holding publ AB
ST:KENH
|
0.127x |
Annual Cash Flow Conversion Efficiency for PATRYS Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of PATRYS Ltd from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see PATRYS Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$732.87K ≈ $518.56K |
AU$-1.77 Million ≈ $-1.26 Million |
-2.421x | -362.62% |
| 2024-06-30 | AU$3.47 Million ≈ $2.46 Million |
AU$-1.82 Million ≈ $-1.28 Million |
-0.523x | +38.08% |
| 2023-06-30 | AU$6.84 Million ≈ $4.84 Million |
AU$-5.78 Million ≈ $-4.09 Million |
-0.845x | -30.75% |
| 2022-06-30 | AU$13.43 Million ≈ $9.50 Million |
AU$-8.68 Million ≈ $-6.14 Million |
-0.646x | -100.76% |
| 2021-06-30 | AU$12.04 Million ≈ $8.52 Million |
AU$-3.88 Million ≈ $-2.74 Million |
-0.322x | +37.06% |
| 2020-06-30 | AU$4.88 Million ≈ $3.45 Million |
AU$-2.50 Million ≈ $-1.77 Million |
-0.512x | -2789.46% |
| 2019-06-30 | AU$7.30 Million ≈ $5.16 Million |
AU$-129.19K ≈ $-91.41K |
-0.018x | +93.81% |
| 2018-06-30 | AU$7.29 Million ≈ $5.16 Million |
AU$-2.09 Million ≈ $-1.48 Million |
-0.286x | +40.32% |
| 2017-06-30 | AU$2.66 Million ≈ $1.88 Million |
AU$-1.28 Million ≈ $-903.55K |
-0.480x | -13.93% |
| 2016-06-30 | AU$3.64 Million ≈ $2.57 Million |
AU$-1.53 Million ≈ $-1.08 Million |
-0.421x | +59.39% |
| 2015-06-30 | AU$3.97 Million ≈ $2.81 Million |
AU$-4.11 Million ≈ $-2.91 Million |
-1.036x | -153.21% |
| 2014-06-30 | AU$12.43 Million ≈ $8.80 Million |
AU$-5.09 Million ≈ $-3.60 Million |
-0.409x | -67.78% |
| 2013-06-30 | AU$10.77 Million ≈ $7.62 Million |
AU$-2.63 Million ≈ $-1.86 Million |
-0.244x | +19.13% |
| 2012-06-30 | AU$12.45 Million ≈ $8.81 Million |
AU$-3.75 Million ≈ $-2.66 Million |
-0.302x | +20.56% |
| 2011-06-30 | AU$13.47 Million ≈ $9.53 Million |
AU$-5.11 Million ≈ $-3.62 Million |
-0.380x | +18.00% |
| 2010-06-30 | AU$15.23 Million ≈ $10.78 Million |
AU$-7.05 Million ≈ $-4.99 Million |
-0.463x | -13.05% |
| 2009-06-30 | AU$17.72 Million ≈ $12.54 Million |
AU$-7.26 Million ≈ $-5.14 Million |
-0.410x | -26.26% |
| 2008-06-30 | AU$22.98 Million ≈ $16.26 Million |
AU$-7.45 Million ≈ $-5.27 Million |
-0.324x | -- |
About PATRYS Ltd
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated wit… Read more